Biocon Biologics settles with Janssen; paves way for launch of biosimilar in US
Thursday, 29 February 2024
Biocon Biologics signs settlement and license agreement with Janssen Biotech and Johnson & Johnson to commercialize Bmab 1200, a biosimilar to Stelara, in the US once approved by the USFDA. The therapy is expected to launch in February 2025.
|
||||
You Might Like |
||||
